Our top pick for
Building a portfolio
Syros Pharmaceuticals, Inc is a biotechnology business based in the US. Syros Pharmaceuticals shares (SYRS) are listed on the NASDAQ and all prices are listed in US Dollars. Syros Pharmaceuticals employs 103 staff and has a trailing 12-month revenue of around USD$15.1 million.
|52-week range||USD$6.4 - USD$15.65|
|50-day moving average||USD$8.6325|
|200-day moving average||USD$9.6464|
|Wall St. target price||USD$16.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.951|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$15.1 million|
|Gross profit TTM||USD$15.1 million|
|Return on assets TTM||-28.32%|
|Return on equity TTM||-99.02%|
|Market capitalisation||USD$422.2 million|
TTM: trailing 12 months
There are currently 4.9 million Syros Pharmaceuticals shares held short by investors – that's known as Syros Pharmaceuticals's "short interest". This figure is 21.2% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting Syros Pharmaceuticals shares can be evaluated.
Syros Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Syros Pharmaceuticals shares currently shorted divided by the average quantity of Syros Pharmaceuticals shares traded daily (recently around 777846.57097289). Syros Pharmaceuticals's SIR currently stands at 6.27. In other words for every 100,000 Syros Pharmaceuticals shares traded daily on the market, roughly 6270 shares are currently held short.
However Syros Pharmaceuticals's short interest can also be evaluated against the total number of Syros Pharmaceuticals shares, or, against the total number of tradable Syros Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syros Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Syros Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1201% of the tradable shares (for every 100,000 tradable Syros Pharmaceuticals shares, roughly 120 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syros Pharmaceuticals.
Find out more about how you can short Syros Pharmaceuticals stock.
We're not expecting Syros Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Syros Pharmaceuticals's shares have ranged in value from as little as $6.4 up to $15.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syros Pharmaceuticals's is 1.9034. This would suggest that Syros Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.